Jorey Chernett Purchases 607,400 Shares of Neuronetics (NASDAQ:STIM) Stock

Neuronetics, Inc. (NASDAQ:STIM) major shareholder Jorey Chernett acquired 607,400 shares of the firm’s stock in a transaction that occurred on Wednesday, March 18th. The stock was acquired at an average cost of $1.35 per share, with a total value of $819,990.00. Following the completion of the acquisition, the insider directly owned 8,123,804 shares in the company, valued at approximately $10,967,135.40. This represents a 8.08% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Jorey Chernett also recently made the following trade(s):

• On Thursday, March 19th, Jorey Chernett purchased 450,000 shares of Neuronetics stock. The shares were acquired at an average price of $1.33 per share, with a total value of $598,500.00.
• On Tuesday, March 17th, Jorey Chernett purchased 531,000 shares of Neuronetics stock. The stock was acquired at an average cost of $1.16 per share, with a total value of $615,960.00.

Neuronetics Price Performance

Shares of STIM opened at $1.45 on Friday. Neuronetics, Inc. has a one year low of $0.80 and a one year high of $5.05. The stock’s fifty day moving average is $1.60 and its 200-day moving average is $2.02. The company has a debt-to-equity ratio of 2.51, a quick ratio of 2.09 and a current ratio of 2.02. The firm has a market capitalization of $100.46 million, a price-to-earnings ratio of -2.46 and a beta of 0.87.

Neuronetics (NASDAQ:STIM) last posted its quarterly earnings data on Tuesday, March 17th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.02. The business had revenue of $41.78 million during the quarter, compared to the consensus estimate of $40.84 million. Neuronetics had a negative net margin of 26.15% and a negative return on equity of 121.26%. Equities analysts anticipate that Neuronetics, Inc. will post -1.13 EPS for the current year.

Analyst Ratings Changes

STIM has been the subject of a number of research reports. Canaccord Genuity Group decreased their price target on Neuronetics from $7.00 to $3.00 and set a “buy” rating for the company in a research note on Thursday. Weiss Ratings reissued a “sell (e+)” rating on shares of Neuronetics in a research note on Thursday, January 22nd. Finally, Wall Street Zen cut Neuronetics from a “hold” rating to a “sell” rating in a research note on Saturday. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $3.00.

Key Neuronetics News

Here are the key news stories impacting Neuronetics this week:

• Positive Sentiment: Major insider buying: Jorey Chernett (a major shareholder) increased his stake with multiple purchases over March 17–19 totaling roughly 1.59M shares across filings, boosting ownership and signaling insider confidence. SEC Form 4 filing Investing.com coverage
• Positive Sentiment: Q4 results modestly beat expectations: EPS of ($0.10) vs. (~$0.12) est. and revenue $41.8M vs. $40.8M expected — a near‑term operational positive but the company remains unprofitable. Earnings call transcript
• Neutral Sentiment: Mixed analyst and institutional profile: MarketBeat notes one Buy and one Sell rating, a consensus “Hold,” active institutional turnover, and wide variance in targets — underlines divergent views and liquidity sensitivity for this small‑cap stock. MarketBeat coverage
• Negative Sentiment: Price‑target reduction from Canaccord: Canaccord cut its target from $7 to $3 (still a Buy), narrowing perceived upside and likely weighing on sentiment despite the maintained rating. Benzinga report
• Negative Sentiment: Short‑term sell pressure / headline reaction: AAII and other outlets highlighted a multi‑percent intraday decline (around 5%), attributing it to the mix of analyst action, profit‑taking after recent moves, and the company’s continued negative margins and leverage. AAII article

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. HighTower Advisors LLC lifted its holdings in shares of Neuronetics by 260.7% in the third quarter. HighTower Advisors LLC now owns 577,069 shares of the company’s stock valued at $1,575,000 after purchasing an additional 417,087 shares in the last quarter. UBS Group AG grew its holdings in shares of Neuronetics by 20.4% during the fourth quarter. UBS Group AG now owns 2,607,047 shares of the company’s stock valued at $3,598,000 after buying an additional 442,216 shares in the last quarter. Presidio Capital Management LLC grew its holdings in shares of Neuronetics by 217.0% during the fourth quarter. Presidio Capital Management LLC now owns 37,436 shares of the company’s stock valued at $52,000 after buying an additional 25,625 shares in the last quarter. David J Yvars Group raised its position in Neuronetics by 22.1% during the fourth quarter. David J Yvars Group now owns 31,230 shares of the company’s stock valued at $43,000 after buying an additional 5,650 shares during the period. Finally, Centiva Capital LP raised its position in Neuronetics by 110.2% during the third quarter. Centiva Capital LP now owns 117,322 shares of the company’s stock valued at $320,000 after buying an additional 61,501 shares during the period. 53.59% of the stock is currently owned by institutional investors and hedge funds.

Neuronetics Company Profile

Neuronetics, Inc is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company’s flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.

Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation.